E2 ModerateModerate confidencePEM unclearCase-ControlPeer-reviewedMachine draft
Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome.
Bennett, A L, Chao, C C, Hu, S et al. · Journal of clinical immunology · 1997 · DOI
Quick Summary
Researchers measured a protein called TGF-beta in the blood of ME/CFS patients and compared it to healthy people and patients with other diseases like lupus and multiple sclerosis. They found that ME/CFS patients had significantly higher levels of this protein than all the other groups studied. This suggests that TGF-beta might play a role in ME/CFS, though more research is needed to understand exactly how.
Why It Matters
This study identifies a measurable biological abnormality in ME/CFS that distinguishes it from other diseases with similar symptoms, potentially supporting the search for objective diagnostic markers. Elevation of TGF-beta, an immunomodulatory cytokine, provides a biological clue to disease mechanisms and could guide future therapeutic research.
Observed Findings
- ME/CFS patients had significantly higher bioactive TGF-beta levels than healthy controls (P < 0.01)
- ME/CFS patients had significantly higher bioactive TGF-beta levels than major depression patients (P < 0.01)
- ME/CFS patients had significantly higher bioactive TGF-beta levels than SLE patients (P < 0.01)
- ME/CFS patients had significantly higher bioactive TGF-beta levels than both R/R MS and CP MS patients (P < 0.01)
- No significant differences in TGF-beta levels were found between healthy controls and any disease comparison group
Inferred Conclusions
- Bioactive TGF-beta is significantly elevated in ME/CFS patients compared to multiple disease and healthy control groups
- TGF-beta elevation may represent a biological marker that distinguishes ME/CFS from other diseases with immunologic abnormalities or pathologic fatigue
- TGF-beta may play a role in ME/CFS pathogenesis, warranting further investigation
Remaining Questions
- What is the functional mechanism by which elevated TGF-beta contributes to ME/CFS symptoms?
- Does TGF-beta elevation precede symptom onset or develop as a consequence of the disease process?
What This Study Does Not Prove
This study does not prove that elevated TGF-beta causes ME/CFS—it only shows an association. It does not determine whether TGF-beta elevation is a primary driver of illness, a secondary consequence of the disease process, or whether lowering TGF-beta would improve symptoms. Cross-sectional measurement cannot establish temporal relationships or mechanistic function.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1023/a:1027330616073
- PMID
- 9083892
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →